Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents [0.03%]
组织不可知型循环肿瘤DNA应答监测在肺癌化疗、免疫治疗或靶向药物治疗中的实际有效性
Anne C Chiang,Russell W Madison,Zoe June Assaf et al.
Anne C Chiang et al.
Introduction: Circulating tumor DNA (ctDNA) monitoring is emerging as a minimally invasive complement to tumor imaging. We evaluated the validity of tissue-agnostic ctDNA quantification across four treatment modalities in...
Midkine Expression as a Candidate Biomarker to Predict the Recurrence of Stage IA Lung Adenocarcinoma [0.03%]
中期因子表达作为IA期肺腺癌复发预测候选标志物
Xiao Yang,Shuo Sun,Xunjie Kuang et al.
Xiao Yang et al.
Background: Early recurrence limits the long-term survival of postoperative patients with stage IA lung adenocarcinoma (LUAD). This study aims to risk-stratify postoperative stage IA LUAD by means of the expression of Mid...
Parallel Phase II Clinical Trials of Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma [0.03%]
用于治疗纵隔顶囊细胞瘤和胸腺癌的同类首个药物XPO1抑制剂塞利尼索的平行II期临床试验
Chul Kim,Vanya Aggarwal,Gedske Daugaard et al.
Chul Kim et al.
Introduction: Thymic epithelial tumors (TETs) are rare and include thymomas (T) and thymic carcinomas (TC). Effective treatment options are needed for patients with progressive disease after platinum-based chemotherapy. P...
BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature [0.03%]
关于BRAF融合作为EGFR突变型非小细胞肺癌患者对奥希替尼耐药机制的病例报告及文献回顾
Marianna Peroni,Alessandro Leonetti,Roberta Minari et al.
Marianna Peroni et al.
Despite the efficacy of osimertinib in the first-line treatment of advanced EGFR-mutated NSCLC, the development of resistance is nearly inevitable. BRAF mutations and fusions are reported in 1% to 3% of patients with EGFR-mutated NSCLC rece...
A Phase II Study of Cabozantinib in Patients With MET-Altered Lung Cancers [0.03%]
卡博替尼治疗MET异常的肺癌患者II期研究
Guilherme Harada,Fernando C Santini,Clare J Wilhelm et al.
Guilherme Harada et al.
Introduction: Only type I MET tyrosine kinase inhibitors (TKIs) are approved for treating MET-altered NSCLCs. Preclinically, type II TKIs, such as cabozantinib, can rescue progression on type I TKIs. This phase 2 trial (N...
A Phase I Dose-Escalation Clinical Trial of Bronchoscopic Cryoimmunotherapy in Advanced-Stage NSCLC [0.03%]
支气管内冷冻免疫治疗晚期非小细胞肺癌I期爬坡剂量临床试验
Jun-Chieh J Tsay,Antonio Velez,Destiny Collazo et al.
Jun-Chieh J Tsay et al.
Introduction: Outcomes for NSCLC remain suboptimal. Recent data suggest that cryoablation can generate antitumor immune effects. In this first-in-human phase I clinical trial, we investigated the safety and feasibility of...
Post-discontinuation Survival in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Pooled Analysis of Prospective Cohort Studies [0.03%]
免疫检查点抑制剂治疗后晚期NSCLC患者预后：前瞻性队列研究汇总分析
Yusuke Inoue,Yoshihiro Kitahara,Masato Karayama et al.
Yusuke Inoue et al.
Introduction: The safety of discontinuing immune checkpoint inhibitors (ICIs) because of a durable response in patients with advanced NSCLC remains uncertain, and post-discontinuation survival outcomes based on the reason...
Lung Cancer Screening Eligibility, Uptake, and Adherence in Puerto Rico, 2022 [0.03%]
2022年波多黎各肺癌筛查的资格、接受率和依从性
Maira A Castañeda-Avila,Eduardo J Santiago-Rodríguez,William Rodríguez-Cintrón et al.
Maira A Castañeda-Avila et al.
Importance: Lung cancer screening (LCS) with yearly low-dose computed tomography reduces lung cancer mortality, but uptake remains low. Puerto Rico, a U.S. territory, faces significant barriers to LCS implementation, but ...
A Prospective Exploratory Study of Functional Immunity Assessed by Pretreatment Interferon Gamma Release Assay in Relation to Different Systemic Therapies in Patients With Advanced-Stage NSCLC [0.03%]
晚期非小细胞肺癌患者不同系统性治疗与治疗前干扰素γ释放试验评估的功能免疫的探索性研究
Hsu-Ching Huang,Han-Jhih Chang,Chi-Lu Chiang et al.
Hsu-Ching Huang et al.
Introduction: Predictive markers for chemotherapy and immunotherapy response in advanced NSCLC are limited, and no objective tool exists to assess immune function, which is critical for treatment outcomes. This study pros...
An Uneven Playing Field: Survival Gains in Stage IV NSCLC Across Sociodemographic Strata [0.03%]
生存差异：不同人口统计学特征的四期非小细胞肺癌患者的生存获益分析
Justin A Olivera,Sara Sakowitz,Mara B Antonoff
Justin A Olivera